Bruker (BRKR) announced that Bruker and 10x Genomics (TXG) have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, will be withdrawn.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- AbCellera says Federal Circuit rejects Bruker Cellular’s invalidity challenge
- Bruker price target lowered to $45 from $57 at UBS
- Bruker price target lowered to $48 from $57 at Stifel
- Bruker price target lowered to $46 from $50 at Barclays
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue